| Withdrawn | NOTIFY (New Observations Taking Information From Yesterday) NCT05977413 | Stanford University | N/A |
| Recruiting | Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patien NCT07034690 | Novartis Pharmaceuticals | Phase 4 |
| Recruiting | Fish Oil, Metformin and Heart Health in PCOS NCT06424860 | University of Alberta | Phase 1 |
| Completed | Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CV NCT07203677 | Brigham and Women's Hospital | — |
| Completed | Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CK NCT07160829 | Novo Nordisk A/S | — |
| Recruiting | Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure NCT06962488 | University of Alabama at Birmingham | N/A |
| Recruiting | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerot NCT07037433 | Amgen | Phase 3 |
| Recruiting | Pelacarsen Roll-over Extension Program NCT06875973 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia NCT06858332 | Novartis Pharmaceuticals | — |
| Recruiting | Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and P NCT06813339 | Cyclarity Therapeutics, Inc. | EARLY_Phase 1 |
| Recruiting | A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic Cardiovasc NCT06571162 | Intermountain Health Care, Inc. | N/A |
| Active Not Recruiting | VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease NCT06249165 | Duke University | Phase 4 |
| Completed | A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Esta NCT06675175 | AstraZeneca | Phase 1 |
| Completed | A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure NCT06692764 | AstraZeneca | Phase 2 |
| Recruiting | The Prevent Coronary Artery Disease Trial NCT06494501 | Icahn School of Medicine at Mount Sinai | Phase 3 |
| Enrolling By Invitation | Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Dise NCT06112327 | Verve Therapeutics, Inc. | — |
| Withdrawn | Immunomodulatory Effects of PCSK9 Inhibition NCT05720156 | Massachusetts General Hospital | — |
| Recruiting | Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Athero NCT06541691 | Rajaie Cardiovascular Medical and Research Center | N/A |
| Completed | In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Est NCT05974345 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus NCT05749874 | China National Center for Cardiovascular Diseases | Phase 4 |
| Completed | YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis NCT06048588 | Beijing Inno Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer NCT05976893 | Xiang Xie | Phase 4 |
| Completed | Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients NCT05761444 | Organon and Co | Phase 4 |
| Unknown | Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvas NCT05705804 | Yonsei University | N/A |
| Completed | Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening (Missing Lipids) NCT05724615 | University of Pennsylvania | N/A |
| Recruiting | LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD) NCT05765370 | China National Center for Cardiovascular Diseases | N/A |
| Completed | Patterns of Inclisiran Use in the Real World: An Analysis of US Databases NCT07023445 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial NCT05581303 | Amgen | Phase 3 |
| Terminated | Tracking of Lipid Lowering Therapy in Jordan NCT05629767 | Jordan Collaborating Cardiology Group | — |
| Unknown | A Study for Exploring the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque NCT05278182 | Chinese Academy of Medical Sciences, Fuwai Hospital | N/A |
| Completed | Time Restricted Eating and Innate Immunity NCT05639244 | Radboud University Medical Center | N/A |
| Recruiting | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing NCT05485961 | CSL Behring | Phase 2 / Phase 3 |
| Completed | A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in NCT06507852 | Novartis | — |
| Completed | Association Between Apical Periodontitis and Atherosclerotic Cardiovascular Diseases NCT05792787 | University of Siena | — |
| Completed | Real Life Lipid Management in Hospitals Not Participating in PENELOPE Trial - Control Population for PENELOPE NCT05659888 | Clinical Operations WCN B.V. | — |
| Completed | A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease NCT05398029 | Verve Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes NCT05294653 | Shanghai Jiao Tong University School of Medicine | — |
| Completed | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atheroscler NCT05355402 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardio NCT05378529 | Amgen | N/A |
| Active Not Recruiting | The Belgian REAL (BE.REAL) Registry NCT05726838 | Novartis Pharmaceuticals | — |
| Completed | Generalizability of REDUCE-IT Results to People of South Asian Descent With Atherosclerotic Cardiovascular Dis NCT05271591 | Canadian Medical and Surgical Knowledge Translation Research Group | — |
| Active Not Recruiting | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease NCT05202509 | NewAmsterdam Pharma | Phase 3 |
| Completed | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies NCT05142722 | NewAmsterdam Pharma | Phase 3 |
| Active Not Recruiting | Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Dise NCT05030428 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY A NCT05129241 | Sanofi | — |
| Completed | A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men NCT05003440 | Novo Nordisk A/S | Phase 1 |
| Completed | A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Dise NCT04992065 | Novo Nordisk A/S | Phase 2 |
| Completed | Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support NCT04807400 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques NCT05639218 | Pauls Stradins Clinical University Hospital | — |
| Completed | A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual C NCT04929249 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Recipe for Heart Health NCT04828447 | University of Florida | N/A |
| Unknown | Incidental Coronary Calcification Quality Improvement Project NCT04789278 | Stanford University | N/A |
| Completed | Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized NCT04626973 | Yonsei University | N/A |
| Unknown | Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascul NCT04338165 | University Hospital, Grenoble | Phase 2 |
| Completed | Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis NCT04271735 | National Heart, Lung, and Blood Institute (NHLBI) | N/A |
| Completed | Compressive Elastic Dressing Versus TR Band NCT05409716 | An-Najah National University | N/A |
| Active Not Recruiting | The Young Heart Study NCT04462159 | Northwell Health | N/A |
| Unknown | Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases NCT04924686 | Zhujiang Hospital | — |
| Unknown | Association Between Dietary Habits and Risk Factors for Atherosclerotic Cardiovascular Diseases in Assiut Gove NCT03505073 | Assiut University | — |
| Completed | Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events NCT04271280 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | — |
| Completed | Behavioral Economic Approaches to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascu NCT03911141 | University of Pennsylvania | N/A |
| Completed | Effect of Evolocumab on Vascular Function NCT03626831 | University of Erlangen-Nürnberg Medical School | Phase 4 |
| Completed | Evaluation of the Novel Use of Gamification With Alternative Goal-setting Experiences NCT03749473 | University of Pennsylvania | N/A |
| Unknown | Mind Our Heart Study NCT03826836 | Catharina Ziekenhuis Eindhoven | N/A |
| Active Not Recruiting | A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular D NCT03705234 | University of Oxford | Phase 3 |
| Completed | Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM NCT03597412 | Yuhan Corporation | Phase 4 |
| Completed | The Learning Registry NCT03911284 | Duke University | — |
| Unknown | High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascul NCT03403556 | Yuhan Corporation | Phase 4 |
| Unknown | How Atorvastatin Affects the Gut Flora and Metabolomics? NCT04215237 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Completed | Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity NCT03096288 | University of Florida | Phase 4 |
| Completed | Subclinical Cardiovascular Disease in Psoriatic Disease NCT03228017 | NYU Langone Health | Phase 4 |
| Completed | An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol NCT03060577 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) NCT03067441 | Esperion Therapeutics, Inc. | Phase 3 |
| Completed | The Effect of Anacetrapib on Vascular Function and Arterial Stiffness NCT02931188 | Cambridge University Hospitals NHS Foundation Trust | — |
| Completed | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiova NCT02991118 | Esperion Therapeutics, Inc. | Phase 3 |
| Completed | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin NCT02988115 | Esperion Therapeutics, Inc. | Phase 3 |
| Withdrawn | Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atheroscleroti NCT02388971 | Takeda | Phase 2 |
| Completed | Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term NCT02697916 | Duke University | N/A |
| Completed | Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) NCT02597127 | The Medicines Company | Phase 2 |
| Completed | Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study NCT02576067 | Icahn School of Medicine at Mount Sinai | Phase 3 |
| Withdrawn | Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis NCT01666704 | Bristol-Myers Squibb | Phase 2 |
| Completed | ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With NCT01663402 | Sanofi | Phase 3 |
| Unknown | Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabo NCT01572259 | Assistance Publique Hopitaux De Marseille | Phase 3 |
| Active Not Recruiting | REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification NCT01252953 | University of Oxford | Phase 3 |
| Unknown | Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atheroscleros NCT01330602 | National University Hospital, Singapore | N/A |
| Completed | Short-term Changes on C-Reactive Protein (CRP) Levels After Non-surgical Periodontal Treatment NCT01433744 | State University of Maringá | N/A |
| Terminated | Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation NCT00856817 | Radboud University Medical Center | Phase 4 |
| Completed | Olmesartan Medoxomil in Atherosclerosis NCT00185185 | Sankyo Pharma Gmbh | Phase 3 |
| Completed | Multicenter Trial of Meditation and Health Education for Cardiometabolic Disease in Black Women NCT06443814 | Robert Schneider, MD | Phase 2 |
| Unknown | Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabet NCT01353066 | Hospital Clinic of Barcelona | Phase 2 / Phase 3 |